Edwin P M Jansen
Overview
Explore the profile of Edwin P M Jansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Dikken J, Verheij M, Cats A, Jansen E, Hartgrink H, van de Velde C
Gastric Cancer
. 2011 Aug;
14(4):396-8.
PMID: 21837457
No abstract available.
32.
Dikken J, van Sandick J, Swellengrebel H, Lind P, Putter H, Jansen E, et al.
BMC Cancer
. 2011 Aug;
11:329.
PMID: 21810227
Background: Radical surgery is the cornerstone in the treatment of resectable gastric cancer. The Intergroup 0116 and MAGIC trials have shown benefit of postoperative chemoradiation and perioperative chemotherapy, respectively. Since...
33.
Courrech Staal E, Aleman B, van Velthuysen M, Cats A, Boot H, Jansen E, et al.
Am J Clin Oncol
. 2010 Jun;
34(4):343-9.
PMID: 20562589
Objectives: The aim of this study was to retrospectively evaluate toxicity and efficacy of 3 chemoradiation regimens. Methods: Between 1997 and 2007, 94 patients with esophageal cancer were treated with...
34.
Dikken J, Jansen E, Cats A, Bakker B, Hartgrink H, Meershoek-Klein Kranenbarg E, et al.
J Clin Oncol
. 2010 Apr;
28(14):2430-6.
PMID: 20368551
Purpose: The Intergroup 0116 trial has demonstrated that postoperative chemoradiotherapy (CRT) improves survival in gastric cancer. We retrospectively compared survival and recurrence patterns in two phase I/II studies evaluating more...
35.
Jansen E, Nijkamp J, Gubanski M, Lind P, Verheij M
Int J Radiat Oncol Biol Phys
. 2009 Oct;
77(4):1166-70.
PMID: 19836158
Purpose: To evaluate interobserver variability in clinical target volume (CTV) delineation in gastric cancer performed with the help of a delineation guide. Patients And Methods: Ten radiotherapy centers that participate...
36.
Hartgrink H, Jansen E, van Grieken N, van de Velde C
Lancet
. 2009 Jul;
374(9688):477-90.
PMID: 19625077
Gastric cancer is the second most frequent cause of cancer death worldwide, although much geographical variation in incidence exists. Prevention and personalised treatment are regarded as the best options to...
37.
Jansen E, Boot H, Saunders M, Crosby T, Dubbelman R, Bartelink H, et al.
Int J Radiat Oncol Biol Phys
. 2007 Aug;
69(5):1424-8.
PMID: 17689023
Background: The Intergroup 0116 randomized study showed that postoperative 5-fluorouracil-based chemoradiotherapy improved locoregional control and overall survival in patients with gastric cancer. We hypothesized that these results could be improved...
38.
Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer
Jansen E, Saunders M, Boot H, Oppedijk V, Dubbelman R, Porritt B, et al.
Int J Radiat Oncol Biol Phys
. 2006 Dec;
67(3):781-5.
PMID: 17157445
Purpose: Postoperative chemoradiotherapy in gastric cancer improves locoregional control and survival. Reports on late toxicity, however, have been scarce thus far. Because renal toxicity is one of the most serious...
39.
Boot H, Jansen E, Cats A
N Engl J Med
. 2006 Oct;
355(13):1387.
PMID: 17014037
No abstract available.
40.
Jansen E, Boot H, Verheij M, van de Velde C
J Clin Oncol
. 2005 Jul;
23(20):4509-17.
PMID: 16002841
Worldwide, gastric cancer is one of the leading causes of cancer-related death. The mainstay of curative treatment is radical surgery. But even with optimal surgical resection, the prognosis remains modest...